Mifepristone is not used in?
**Core Concept**
Mifepristone is a synthetic steroid with potent antiglucocorticoid and antiprogestin activities. It acts as a competitive antagonist at the glucocorticoid receptor and progesterone receptor, thereby modulating various physiological processes.
**Why the Correct Answer is Right**
Mifepristone is primarily used in medical abortion and as an adjunct therapy in Cushing's syndrome due to its ability to block cortisol and progesterone effects. Its antiglucocorticoid properties help in reducing cortisol-mediated symptoms in Cushing's syndrome, while its antiprogestin properties induce uterine contractions and prepare the uterine lining for abortion. Mifepristone's mechanism of action involves binding to the glucocorticoid receptor and inhibiting the transcription of glucocorticoid-responsive genes.
**Why Each Wrong Option is Incorrect**
**Option A:** Mifepristone is not used in the treatment of premenstrual dysphoric disorder (PMDD). This is because its mechanism of action does not directly address the hormonal imbalances and mood fluctuations associated with PMDD.
**Option B:** Mifepristone is not used as a treatment for postmenopausal osteoporosis. While glucocorticoids can contribute to osteoporosis, mifepristone's antiglucocorticoid effects are not sufficient to prevent bone loss in postmenopausal women.
**Option C:** Mifepristone is not used as a treatment for polycystic ovary syndrome (PCOS). Although mifepristone may modulate androgen and estrogen levels, its primary use is not in the management of PCOS symptoms.
**Option D:** Mifepristone is not used as a treatment for thyroid hormone replacement therapy. Mifepristone's antiglucocorticoid effects do not directly impact thyroid hormone levels or function.
**Clinical Pearl / High-Yield Fact**
Mifepristone's antiglucocorticoid effects can lead to an increase in plasma renin activity and aldosterone levels, potentially causing electrolyte imbalances and hypokalemia. This highlights the importance of monitoring electrolyte levels in patients receiving mifepristone.
**Correct Answer:** D.